Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial.

Sundar R, Ng A, Zouridis H, Padmanabhan N, Sheng T, Zhang S, Lee MH, Ooi WF, Qamra A, Inam I, Hewitt LC, So JB, Koh V, Nankivell MG, Langley RE, Allum WH, Cunningham D, Rozen SG, Yong WP, Grabsch HI, Tan P.

Eur J Cancer. 2019 Oct 23;123:48-57. doi: 10.1016/j.ejca.2019.09.016. [Epub ahead of print]

PMID:
31655359
2.

FBXW5 Promotes Tumorigenesis and Metastasis in Gastric Cancer via Activation of the FAK-Src Signaling Pathway.

Yeo MS, Subhash VV, Suda K, Balcıoğlu HE, Zhou S, Thuya WL, Loh XY, Jammula S, Peethala PC, Tan SH, Xie C, Wong FY, Ladoux B, Ito Y, Yang H, Goh BC, Wang L, Yong WP.

Cancers (Basel). 2019 Jun 17;11(6). pii: E836. doi: 10.3390/cancers11060836.

3.

PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein.

Thura M, Al-Aidaroos AQ, Gupta A, Chee CE, Lee SC, Hui KM, Li J, Guan YK, Yong WP, So J, Chng WJ, Ng CH, Zhou J, Wang LZ, Yuen JSP, Ho HSS, Yi SM, Chiong E, Choo SP, Ngeow J, Ng MCH, Chua C, Yeo ESA, Tan IBH, Sng JXE, Tan NYZ, Thiery JP, Goh BC, Zeng Q.

Nat Commun. 2019 Jun 6;10(1):2484. doi: 10.1038/s41467-019-10127-x.

4.

Study protocol: phase 1 dose escalating study of Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) with oxaliplatin in peritoneal metastasis.

Kim G, Tan HL, Chen E, Teo SC, Jang CJM, Ho J, Ang Y, Ngoi NYL, Chee CE, Lieske B, Shabbir A, Wang LZ, So JBY, Yong WP.

Pleura Peritoneum. 2018 Aug 29;3(3):20180118. doi: 10.1515/pp-2018-0118. eCollection 2018 Sep 1.

5.

Predictors of survival outcome following radical gastrectomy for gastric cancer.

Lui SA, Tan WB, Tai BC, Yong WP, Mu YS, Ti TK, Shabbir A, So J.

ANZ J Surg. 2019 Jan;89(1-2):84-89. doi: 10.1111/ans.15011. Epub 2019 Jan 28.

PMID:
30690932
6.

The Pathway to Intelligence: Using Stimuli-Responsive Materials as Building Blocks for Constructing Smart and Functional Systems.

Zhang X, Chen L, Lim KH, Gonuguntla S, Lim KW, Pranantyo D, Yong WP, Yam WJT, Low Z, Teo WJ, Nien HP, Loh QW, Soh S.

Adv Mater. 2019 Mar;31(11):e1804540. doi: 10.1002/adma.201804540. Epub 2019 Jan 9. Review.

PMID:
30624820
7.

An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma.

El Dika I, Lim HY, Yong WP, Lin CC, Yoon JH, Modiano M, Freilich B, Choi HJ, Chao TY, Kelley RK, Brown J, Knox J, Ryoo BY, Yau T, Abou-Alfa GK.

Oncologist. 2019 Jun;24(6):747-e218. doi: 10.1634/theoncologist.2018-0838. Epub 2018 Dec 31.

8.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS.

Muro K, Van Cutsem E, Narita Y, Pentheroudakis G, Baba E, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh KH, Kato K, Lu Z, Cho BC, Nor IM, Ng M, Chen LT, Nakajima TE, Shitara K, Kawakami H, Tsushima T, Yoshino T, Lordick F, Martinelli E, Smyth EC, Arnold D, Minami H, Tabernero J, Douillard JY.

Ann Oncol. 2019 Jan 1;30(1):19-33. doi: 10.1093/annonc/mdy502.

PMID:
30475956
9.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS.

Muro K, Lordick F, Tsushima T, Pentheroudakis G, Baba E, Lu Z, Cho BC, Nor IM, Ng M, Chen LT, Kato K, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh KH, Nakajima TE, Shitara K, Kawakami H, Narita Y, Yoshino T, Van Cutsem E, Martinelli E, Smyth EC, Arnold D, Minami H, Tabernero J, Douillard JY.

Ann Oncol. 2019 Jan 1;30(1):34-43. doi: 10.1093/annonc/mdy498.

PMID:
30475943
10.

A Review on Liquid Chromatography-Tandem Mass Spectrometry Methods for Rapid Quantification of Oncology Drugs.

Wong AL, Xiang X, Ong PS, Mitchell EQY, Syn N, Wee I, Kumar AP, Yong WP, Sethi G, Goh BC, Ho PC, Wang L.

Pharmaceutics. 2018 Nov 8;10(4). pii: E221. doi: 10.3390/pharmaceutics10040221. Review.

11.

The Role of Liver-Directed Therapy in Metastatic Colorectal Cancer.

Tan HL, Lee M, Vellayappan BA, Neo WT, Yong WP.

Curr Colorectal Cancer Rep. 2018;14(5):129-137. doi: 10.1007/s11888-018-0409-6. Epub 2018 Sep 13. Review.

12.

An anti-ASCT2 monoclonal antibody suppresses gastric cancer growth by inducing oxidative stress and antibody dependent cellular toxicity in preclinical models.

Osanai-Sasakawa A, Hosomi K, Sumitomo Y, Takizawa T, Tomura-Suruki S, Imaizumi M, Kasai N, Poh TW, Yamano K, Yong WP, Kono K, Nakamura S, Ishii T, Nakai R.

Am J Cancer Res. 2018 Aug 1;8(8):1499-1513. eCollection 2018.

13.

Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor.

Subhash VV, Yeo MS, Wang L, Tan SH, Wong FY, Thuya WL, Tan WL, Peethala PC, Soe MY, Tan DSP, Padmanabhan N, Baloglu E, Shacham S, Tan P, Koeffler HP, Yong WP.

Sci Rep. 2018 Aug 16;8(1):12248. doi: 10.1038/s41598-018-30686-1.

14.

A Sensitive Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Nimbolide in Mouse Serum: Application to a Preclinical Pharmacokinetics Study.

Wang L, Phan DK, Syn N, Xiang X, Song H, Thuya WL, Yang S, Wong AL, Kumar AP, Yong WP, Sethi G, Ho PC, Goh BC.

Pharmaceutics. 2018 Aug 8;10(3). pii: E123. doi: 10.3390/pharmaceutics10030123.

15.

Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" Trial.

Yong WP, Rha SY, Tan IB, Choo SP, Syn NL, Koh V, Tan SH, Asuncion BR, Sundar R, So JB, Shabbir A, Tan CS, Kim HS, Jung M, Chung HC, Ng MCH, Tai DW, Lee MH, Wu J, Yeoh KG, Tan P; Singapore Gastric Cancer Consortium (SGCC).

Clin Cancer Res. 2018 Nov 1;24(21):5272-5281. doi: 10.1158/1078-0432.CCR-18-0193. Epub 2018 Jul 25.

16.

Discovering novel SNPs that are correlated with patient outcome in a Singaporean cancer patient cohort treated with gemcitabine-based chemotherapy.

Limviphuvadh V, Tan CS, Konishi F, Jenjaroenpun P, Xiang JS, Kremenska Y, Mu YS, Syn N, Lee SC, Soo RA, Eisenhaber F, Maurer-Stroh S, Yong WP.

BMC Cancer. 2018 May 11;18(1):555. doi: 10.1186/s12885-018-4471-x.

17.

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.

Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, Harvey RD, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, Stadler WM, Ratain MJ.

J Clin Oncol. 2018 May 10;36(14):1389-1395. doi: 10.1200/JCO.2017.76.4381. Epub 2018 Mar 28.

18.

A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer.

Sundar R, Rha SY, Yamaue H, Katsuda M, Kono K, Kim HS, Kim C, Mimura K, Kua LF, Yong WP.

BMC Cancer. 2018 Mar 27;18(1):332. doi: 10.1186/s12885-018-4234-8.

19.

Longitudinal monitoring reveals dynamic changes in circulating tumor cells (CTCs) and CTC-associated miRNAs in response to chemotherapy in metastatic colorectal cancer patients.

Tan K, Leong SM, Kee Z, Caramat PV, Teo J, Blanco MVM, Koay ESC, Cheong WK, Soh TI, Yong WP, Pang A.

Cancer Lett. 2018 Jun 1;423:1-8. doi: 10.1016/j.canlet.2018.02.039. Epub 2018 Mar 5.

PMID:
29518480
20.

Resisting resistance to cancer immunotherapy.

Lam WS, Wang LZ, Roudi R, Yong WP, Syn NL, Sundar R.

Thorac Cancer. 2018 May;9(5):507-508. doi: 10.1111/1759-7714.12614. Epub 2018 Mar 7. No abstract available.

21.

Pan-HDAC inhibition by panobinostat mediates chemosensitization to carboplatin in non-small cell lung cancer via attenuation of EGFR signaling.

Wang L, Syn NL, Subhash VV, Any Y, Thuya WL, Cheow ESH, Kong L, Yu F, Peethala PC, Wong AL, Laljibhai HJ, Chinnathambi A, Ong PS, Ho PC, Sethi G, Yong WP, Goh BC.

Cancer Lett. 2018 Mar 28;417:152-160. doi: 10.1016/j.canlet.2017.12.030. Epub 2018 Jan 4.

PMID:
29306016
22.

Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience.

Tseng MSF, Zheng H, Ng IWS, Leong YH, Leong CN, Yong WP, Cheong WK, Tey JCS.

Singapore Med J. 2018 Jun;59(6):305-310. doi: 10.11622/smedj.2017105. Epub 2017 Nov 13.

23.

A phase II trial of preoperative concurrent chemotherapy and dose escalated intensity modulated radiotherapy (IMRT) for locally advanced rectal cancer.

Tey J, Leong CN, Cheong WK, Sze TG, Yong WP, Tham IWK, Lee KM.

J Cancer. 2017 Sep 6;8(16):3114-3121. doi: 10.7150/jca.21237. eCollection 2017.

24.

PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer.

Mimura K, Teh JL, Okayama H, Shiraishi K, Kua LF, Koh V, Smoot DT, Ashktorab H, Oike T, Suzuki Y, Fazreen Z, Asuncion BR, Shabbir A, Yong WP, So J, Soong R, Kono K.

Cancer Sci. 2018 Jan;109(1):43-53. doi: 10.1111/cas.13424. Epub 2017 Nov 18.

25.

Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) Study.

Heong V, Syn NL, Lee XW, Sapari NS, Koh XQ, Adam Isa ZF, Sy Lim J, Lim D, Pang B, Thian YL, Ng LK, Wong AL, Soo RA, Yong WP, Chee CE, Lee SC, Goh BC, Soong R, Tan DSP.

Int J Cancer. 2018 May 1;142(9):1890-1900. doi: 10.1002/ijc.31091. Epub 2017 Oct 17.

26.

Acquired Resistance to FGFR Inhibitor in Diffuse-Type Gastric Cancer through an AKT-Independent PKC-Mediated Phosphorylation of GSK3β.

Lau WM, Teng E, Huang KK, Tan JW, Das K, Zang Z, Chia T, Teh M, Kono K, Yong WP, Shabbir A, Tay A, Phua NS, Tan P, Chan SL, So JBY.

Mol Cancer Ther. 2018 Jan;17(1):232-242. doi: 10.1158/1535-7163.MCT-17-0367. Epub 2017 Oct 4.

27.

Chemotherapy for advanced gastric cancer.

Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, Ho J, Unverzagt S.

Cochrane Database Syst Rev. 2017 Aug 29;8:CD004064. doi: 10.1002/14651858.CD004064.pub4. Review.

28.

Anti-tumor efficacy evaluation of a novel monoclonal antibody targeting neutral amino acid transporter ASCT2 using patient-derived xenograft mouse models of gastric cancer.

Kasai N, Sasakawa A, Hosomi K, Poh TW, Chua BL, Yong WP, So J, Chan SL, Soong R, Kono K, Ishii T, Yamano K.

Am J Transl Res. 2017 Jul 15;9(7):3399-3410. eCollection 2017.

29.

A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).

Tai WM, Yong WP, Lim C, Low LS, Tham CK, Koh TS, Ng QS, Wang WW, Wang LZ, Hartono S, Thng CH, Huynh H, Lim KT, Toh HC, Goh BC, Choo SP.

Ann Oncol. 2018 Feb 1;29(2):526. doi: 10.1093/annonc/mdx060. No abstract available.

PMID:
28368515
30.

Upregulation of thioredoxin-1 in activated human NK cells confers increased tolerance to oxidative stress.

Mimura K, Kua LF, Shimasaki N, Shiraishi K, Nakajima S, Siang LK, Shabbir A, So J, Yong WP, Kono K.

Cancer Immunol Immunother. 2017 May;66(5):605-613. doi: 10.1007/s00262-017-1969-z. Epub 2017 Feb 21.

PMID:
28224212
31.

Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1.

Wang L, Chan CEL, Wong AL, Wong FC, Lim SW, Chinnathambi A, Alharbi SA, Lee LS, Soo R, Yong WP, Lee SC, Ho PC, Sethi G, Goh BC.

Oncotarget. 2017 Jun 20;8(25):41572-41581. doi: 10.18632/oncotarget.15017.

32.

Knockdown of POLA2 increases gemcitabine resistance in lung cancer cells.

Koh V, Kwan HY, Tan WL, Mah TL, Yong WP.

BMC Genomics. 2016 Dec 22;17(Suppl 13):1029. doi: 10.1186/s12864-016-3322-x.

33.

Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready?

Chan DY, Syn NL, Yap R, Phua JN, Soh TI, Chee CE, Nga ME, Shabbir A, So JB, Yong WP.

J Gastrointest Surg. 2017 Mar;21(3):425-433. doi: 10.1007/s11605-016-3336-3. Epub 2016 Dec 15.

PMID:
27981493
34.

Intraperitoneal chemotherapy for gastric cancer with peritoneal disease: experience from Singapore and Japan.

Kono K, Yong WP, Okayama H, Shabbir A, Momma T, Ohki S, Takenoshita S, So J.

Gastric Cancer. 2017 Mar;20(Suppl 1):122-127. doi: 10.1007/s10120-016-0660-y. Epub 2016 Oct 20. Review.

PMID:
27766496
35.

PRL3-zumab, a first-in-class humanized antibody for cancer therapy.

Thura M, Al-Aidaroos AQO, Yong WP, Kono K, Gupta A, Lin YB, Mimura K, Thiery JP, Goh BC, Tan P, Soo R, Hong CW, Wang L, Lin SJ, Chen E, Rha SY, Chung HC, Li J, Nandi S, Yuen HF, Zhang SD, Guan YK, So J, Zeng Q.

JCI Insight. 2016 Jun 16;1(9):e87607. doi: 10.1172/jci.insight.87607.

36.

Accumulation of CD11c+CD163+ Adipose Tissue Macrophages through Upregulation of Intracellular 11β-HSD1 in Human Obesity.

Nakajima S, Koh V, Kua LF, So J, Davide L, Lim KS, Petersen SH, Yong WP, Shabbir A, Kono K.

J Immunol. 2016 Nov 1;197(9):3735-3745. Epub 2016 Oct 3.

37.

A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).

Tai WM, Yong WP, Lim C, Low LS, Tham CK, Koh TS, Ng QS, Wang WW, Wang LZ, Hartano S, Thng CH, Huynh H, Lim KT, Toh HC, Goh BC, Choo SP.

Ann Oncol. 2016 Dec;27(12):2210-2215. doi: 10.1093/annonc/mdw415. Epub 2016 Sep 28. Erratum in: Ann Oncol. 2018 Feb 1;29(2):526.

PMID:
27681866
38.

Capecitabine pharmacogenetics: historical milestones and progress toward clinical implementation.

Syn N, Lee SC, Goh BC, Yong WP.

Pharmacogenomics. 2016 Oct;17(15):1607-1610. Epub 2016 Sep 27. No abstract available.

39.

ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis.

Subhash VV, Tan SH, Yeo MS, Yan FL, Peethala PC, Liem N, Krishnan V, Yong WP.

Mol Cancer Ther. 2016 Dec;15(12):3087-3096. Epub 2016 Sep 16.

40.

Identification of Gastric Cancer Biomarkers Using 1H Nuclear Magnetic Resonance Spectrometry.

Ramachandran GK, Yong WP, Yeow CH.

PLoS One. 2016 Sep 9;11(9):e0162222. doi: 10.1371/journal.pone.0162222. eCollection 2016.

41.

A novel combinatorial strategy using Seliciclib(®) and Belinostat(®) for eradication of non-small cell lung cancer via apoptosis induction and BID activation.

Ong PS, Wang L, Chia DM, Seah JY, Kong LR, Thuya WL, Chinnathambi A, Lau JY, Wong AL, Yong WP, Yang D, Ho PC, Sethi G, Goh BC.

Cancer Lett. 2016 Oct 10;381(1):49-57. doi: 10.1016/j.canlet.2016.07.023. Epub 2016 Jul 25.

PMID:
27461583
42.

CEACAM6 is upregulated by Helicobacter pylori CagA and is a biomarker for early gastric cancer.

Roy RK, Hoppe MM, Srivastava S, Samanta A, Sharma N, Tan KT, Yang H, Voon DC, Pang B, Teh M, Murata-Kamiya N, Hatakeyama M, Chang YT, Yong WP, Ito Y, Ho KY, Tan P, Soong R, Koeffler PH, Yeoh KG, Jeyasekharan AD.

Oncotarget. 2016 Aug 23;7(34):55290-55301. doi: 10.18632/oncotarget.10528.

43.

Pharmacogenetics-Guided Phase I Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid Tumours.

Soo RA, Syn N, Lee SC, Wang L, Lim XY, Loh M, Tan SH, Zee YK, Wong AL, Chuah B, Chan D, Lim SE, Goh BC, Soong R, Yong WP.

Sci Rep. 2016 Jun 14;6:27826. doi: 10.1038/srep27826.

44.

Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.

Syn NL, Yong WP, Goh BC, Lee SC.

Expert Opin Drug Metab Toxicol. 2016 Aug;12(8):911-22. doi: 10.1080/17425255.2016.1196187. Epub 2016 Jun 13. Review.

PMID:
27249175
45.

Gelsolin-mediated activation of PI3K/Akt pathway is crucial for hepatocyte growth factor-induced cell scattering in gastric carcinoma.

Huang B, Deng S, Loo SY, Datta A, Yap YL, Yan B, Ooi CH, Dinh TD, Zhuo J, Tochhawng L, Gopinadhan S, Jegadeesan T, Tan P, Salto-Tellez M, Yong WP, Soong R, Yeoh KG, Goh YC, Lobie PE, Yang H, Kumar AP, Maciver SK, So JB, Yap CT.

Oncotarget. 2016 May 3;7(18):25391-407. doi: 10.18632/oncotarget.8603.

46.

Anticancer properties of nimbolide and pharmacokinetic considerations to accelerate its development.

Wang L, Phan DD, Zhang J, Ong PS, Thuya WL, Soo R, Wong AL, Yong WP, Lee SC, Ho PC, Sethi G, Goh BC.

Oncotarget. 2016 Jul 12;7(28):44790-44802. doi: 10.18632/oncotarget.8316. Review.

47.

Inhibition of MMP activity can restore NKG2D ligand expression in gastric cancer, leading to improved NK cell susceptibility.

Shiraishi K, Mimura K, Kua LF, Koh V, Siang LK, Nakajima S, Fujii H, Shabbir A, Yong WP, So J, Takenoshita S, Kono K.

J Gastroenterol. 2016 Dec;51(12):1101-1111. Epub 2016 Mar 22.

PMID:
27002316
48.

Translating gastric cancer genomics into targeted therapies.

Ang YL, Yong WP, Tan P.

Crit Rev Oncol Hematol. 2016 Apr;100:141-6. doi: 10.1016/j.critrevonc.2016.02.007. Epub 2016 Feb 18. Review.

49.

Melanoma associated antigen (MAGE)-A3 promotes cell proliferation and chemotherapeutic drug resistance in gastric cancer.

Xie C, Subhash VV, Datta A, Liem N, Tan SH, Yeo MS, Tan WL, Koh V, Yan FL, Wong FY, Wong WK, So J, Tan IB, Padmanabhan N, Yap CT, Tan P, Goh LK, Yong WP.

Cell Oncol (Dordr). 2016 Apr;39(2):175-86. doi: 10.1007/s13402-015-0261-5. Epub 2016 Feb 11.

PMID:
26868260
50.

Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI.

Lee LS, Seng KY, Wang LZ, Yong WP, Hee KH, Soh TI, Wong A, Cheong PF, Soong R, Sapari NS, Soo R, Fan L, Lee SC, Goh BC.

PLoS One. 2016 Jan 25;11(1):e0147681. doi: 10.1371/journal.pone.0147681. eCollection 2016.

Supplemental Content

Support Center